ArticleG3 (Bethesda, Md.)2026
In vivo screen for osteoclast derived osteogenic factors using non-resorptive osteoclasts in zebrafish bone.
Article in G3 (Bethesda, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bone homeostasis requires the balanced action of bone forming osteoblasts and bone resorbing osteoclasts. This balance is maintained through local as well as systemic factors. Loss of osteoclast resorptive activity leads to development of osteopetrosis with increased bone volume but reduced skeletal integrity. Identification of the factors that regulate such anabolic activity is hampered by the essential function of these genes in development as well as the inaccessibility of large numbers of primary osteoclasts for biochemical analyses. Here, we generated zebrafish with nonresorptive osteoclasts through CRISPR-Cas9 mediated knockout of chloride voltage-gated channel 7 (clcn7). The clcn7 mutants are adult viable, show increased vertebral bone thickness and increased bone formation. Using this in vivo model of persistent, but deficient osteoclasts, we used differential gene expression to identify putative anabolic bone regulators. Transcriptional profiling of clcn7 mutant primary osteoclasts identified differential expression of genes involved in chemotaxis and cytokine signaling. Global transgenic overexpression of a subset of the upregulated, secreted genes showed positive effects of the cytokines csf3b, cxcl19, and the glycosylated peptide progranulin 1 on skeletal parameters, while the cytokine ccl35.1 negatively impacted bone volume. Our findings suggest that the concerted function of these cytokines plays an important role in the regulation of bone homeostasis and that individual cytokines cause distinct changes in vertebral bone form and differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.